An orally active angiotensin IV analogue designed for CNS penetration that promotes synaptogenesis and demonstrates remarkable cognitive enhancement in animal models.
Sourced from Ascension Peptides. Verified purity, third-party tested. COA included.
Buy Now →Dihexa is a synthetic peptide developed at Washington State University (WSU) by a research team led by Dr. Joseph Harding and Dr. John Wright, who spent years investigating the pharmacological manipulation of the hepatocyte growth factor (HGF) signaling system in the context of cognitive function. Officially designated N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, Dihexa belongs to a class of angiotensin IV analogs — peptides structurally related to the hexapeptide angiotensin IV (Ang IV), itself the shortest active fragment of the renin-angiotensin system. The name “Dihexa” is derived from the Greek prefix for six, referencing its six-residue pharmacophore architecture.
What catapulted Dihexa into the neuroscience spotlight was a remarkable claim from the WSU team: in preclinical models of cognitive impairment, Dihexa was reported to be approximately 10 million times (107-fold) more potent than brain-derived neurotrophic factor (BDNF) in inducing synaptogenesis and rescuing spatial learning deficits. BDNF is widely considered one of the most powerful neurotrophic growth factors known, so the comparison was deliberately provocative and generated significant scientific discussion about mechanisms, specificity, and translational potential. Understanding this claim requires understanding what Dihexa actually does at the molecular level.
Rather than acting as a direct HGF mimetic, Dihexa functions as a potentiator — it dramatically increases the binding affinity of HGF for its receptor, c-Met (also called the MET receptor tyrosine kinase), by reducing the concentration of HGF required to activate c-Met signaling to a biologically meaningful level. This allosteric mechanism means Dihexa works in concert with endogenous HGF, amplifying a signaling pathway that already exists in the brain rather than introducing a foreign stimulus. HGF/c-Met signaling is known to promote neuronal survival, axonal growth, dendrite branching, and synaptic plasticity — all of which contribute to learning and memory functions.
Dihexa also exhibits impressive pharmacological properties that separate it from most peptide research compounds: it demonstrates oral bioavailability and central nervous system penetration in rodent studies, properties that are extremely unusual for peptides and that have driven interest in its potential as a scaffold for orally administered nootropic research tools.
Explore how Dihexa’s mechanism compares to other cognitive peptides in the Peptide Database, or model research doses with the Peptides Helper calculators.
The central mechanistic insight behind Dihexa is that it does not simply bind the c-Met receptor directly as an agonist, nor does it act as HGF itself. Instead, Dihexa appears to dramatically increase the binding affinity of endogenous HGF for c-Met through an allosteric interaction — functioning as a positive allosteric modulator of the ligand-receptor interaction. The WSU research group proposed that Dihexa binds to HGF itself, creating an HGF-Dihexa complex that presents to c-Met with far higher apparent affinity than HGF alone. The consequence is that physiologically low concentrations of HGF in the brain — which might otherwise be insufficient to sustain robust c-Met activation — become capable of triggering full downstream signaling cascades. This allosteric mechanism explains the extraordinary potency comparison to BDNF in quantitative synaptogenesis assays: the dose of Dihexa needed to produce a synaptogenic response comparable to BDNF’s is vastly lower because Dihexa is amplifying an existing signal rather than providing one. It is also worth noting that c-Met is expressed abundantly in hippocampal pyramidal neurons, dentate gyrus granule cells, and cortical neurons — precisely the populations that underlie spatial learning and memory consolidation — making this receptor a biologically coherent target for cognitive research.
When HGF binds and activates c-Met, the receptor’s intrinsic tyrosine kinase domain undergoes autophosphorylation at multiple docking sites that recruit adaptor proteins including Grb2, Gab1, and PI3K. This initiates at least two major parallel downstream signaling cascades. The PI3K/Akt pathway promotes neuronal survival, inhibits pro-apoptotic signals, activates mTOR (which drives protein synthesis required for structural synaptic changes), and phosphorylates CREB — a transcription factor whose activation is essential for long-term memory formation. Simultaneously, the Ras/MAPK (ERK1/2) cascade stimulates gene expression programs associated with neurite outgrowth, dendritic arborization, and synaptic protein synthesis including PSD-95, synaptophysin, and AMPA receptor subunits. The synergistic activation of both pathways through a single allosteric enhancement point is likely why Dihexa produces effects on multiple dimensions of synaptic biology simultaneously — survival, growth, structural remodeling, and functional strengthening — rather than affecting only one component of synaptic plasticity. This multi-pathway activation may also partially explain the dramatic potency advantage over BDNF, which primarily signals through TrkB and produces a somewhat different downstream profile.
The most structurally dramatic evidence for Dihexa’s pro-cognitive mechanism comes from morphological studies demonstrating that it drives de novo formation of dendritic spines — the tiny protrusions on dendrites that house the postsynaptic density of excitatory synapses. Spine density is closely correlated with cognitive capacity, and loss of spines in aging and neurodegeneration is thought to contribute directly to cognitive decline. HGF/c-Met activation promotes spine formation through Rho-family GTPase signaling (particularly Rac1 and Cdc42), which reorganizes the actin cytoskeleton into the branched structures that underlie spine morphology. Critically, the formation of mature, stable spines also requires remodeling of the extracellular matrix (ECM) that surrounds synapses. This is where matrix metalloproteinases (MMPs), particularly MMP-9, come in: Dihexa appears to activate MMP-9 expression and secretion in a c-Met-dependent manner, and MMP-9 cleaves ECM components like laminin and aggrecan that would otherwise physically constrain new spine formation. MMP-9 also cleaves pro-BDNF to its mature form and processes other latent neurotrophic factors, potentially creating a self-amplifying local neurotrophic environment. The combination of cytoskeletal drive and ECM permissiveness makes Dihexa-driven synaptogenesis structurally robust compared to transient functional potentiation.
The foundational Dihexa research, published by Benoist et al. and the Harding/Wright laboratory at Washington State University, used aged rats and scopolamine-treated young rats as models of cognitive impairment. In the Morris water maze, both populations showed severely impaired spatial learning compared to unimpaired controls — they took longer to find the hidden platform, made more errors, and showed poor probe trial performance indicating weak spatial memory consolidation. Dihexa treatment, administered peripherally at doses in the microgram-per-kilogram range, produced statistically significant and substantial improvements in both acquisition speed and probe trial performance. Importantly, the researchers observed that Dihexa had minimal effects on spatial learning in young, unimpaired animals — suggesting it operates preferentially in a state of synaptic deficit rather than producing indiscriminate global enhancement. This selectivity is theoretically important: a compound that only enhances cognition when there is underlying impairment has a fundamentally different safety and utility profile than one that simply over-activates the system regardless of baseline state. The c-Met dependency of these effects was confirmed using pharmacological c-Met inhibitors that blocked Dihexa’s benefits, providing mechanistic linkage between HGF potentiation and cognitive outcome.
Beyond behavioral outcomes, the WSU research group conducted detailed morphological analyses of hippocampal tissue from Dihexa-treated animals and hippocampal slice cultures exposed to Dihexa in vitro. Golgi staining and confocal microscopy revealed significantly increased dendritic spine density in CA1 pyramidal neurons of treated animals compared to vehicle controls. In organotypic hippocampal slice cultures, Dihexa treatment produced measurable increases in miniature excitatory postsynaptic current (mEPSC) frequency — a functional electrophysiological indicator of increased synapse number or release probability. These findings were used to generate the 107-fold potency comparison to BDNF: in the synaptogenesis assay, the molar concentration of Dihexa required to produce a half-maximal synaptogenic response was approximately 10 million times lower than the concentration of BDNF required to produce the same response. While this comparison is methodologically specific to that assay and cannot be generalized as a universal pharmacological equivalency, it does convey that Dihexa’s mechanism produces synaptogenic effects at extraordinarily low concentrations. Whether this extraordinary potency advantage translates proportionally into cognitive outcomes remains an open research question.
A significant fraction of the scientific interest in Dihexa stems from its oral bioavailability — a property that is nearly unheard of in the peptide pharmacology literature. Standard peptides are hydrolyzed in the gastrointestinal tract and, even if absorbed, face substantial first-pass hepatic metabolism that typically renders oral peptide dosing ineffective. Dihexa’s hexanoyl (six-carbon fatty acid) modification at the N-terminus dramatically changes its biophysical properties: it increases lipophilicity (log P shift), enhances membrane permeability, and appears to confer sufficient protease resistance to survive gastrointestinal transit at meaningful levels. Pharmacokinetic studies in rodents confirmed detectable plasma levels following oral gavage and demonstrated CNS penetration, with measurable radioactivity in brain tissue following labeled compound administration. The behavioral studies that demonstrated cognitive rescue in impaired animals were conducted using oral administration in several cases, providing functional confirmation that the oral route produces CNS-active concentrations. This profile makes Dihexa an exceptional research tool and a compelling lead compound for further medicinal chemistry optimization toward orally bioavailable cognitive therapeutics.
The most translatable research context for Dihexa involves Alzheimer’s disease (AD) and other neurodegenerative conditions characterized by synapse loss. AD pathology is strongly correlated with synaptic loss — the reduction in synapse number and density in hippocampus and association cortex is one of the best morphological correlates of cognitive decline in AD, and it precedes significant neuronal death. HGF levels in the brain show a complex pattern in AD: some studies report compensatory upregulation, while c-Met receptor expression and signaling competence may be compromised. If Dihexa can boost the efficiency of residual HGF/c-Met signaling even in a pathologically compromised environment, it could represent a means of partially restoring synaptic function without requiring correction of upstream amyloid or tau pathology. Preclinical studies have explored Dihexa in APP/PS1 transgenic mice with promising initial results on spatial memory and synaptic protein expression, though this literature is limited and replication across independent groups is needed. The compound’s oral bioavailability and CNS penetration make it eminently feasible for chronic treatment paradigms required to model therapeutic use in progressive neurodegeneration.
While the most robust effects are observed in impaired models, several research groups have explored whether Dihexa produces any measurable cognitive enhancement in non-impaired young adult animals. Results here are considerably more mixed. Some studies report modest improvements in complex learning tasks, while others find no significant effect above baseline in healthy animals. This pattern is consistent with the hypothesis that Dihexa’s HGF-potentiating mechanism is most effective when baseline HGF/c-Met signaling is sub-optimal — whether due to aging, injury, neurodegeneration, or pharmaceutical disruption (as with scopolamine). In healthy young animals, endogenous HGF/c-Met tone may already be sufficient for optimal synaptic function, leaving little room for potentiation to produce behavioral improvements. This selectivity profile, if confirmed in further research, would distinguish Dihexa from compounds that produce broad pharmacological stimulation regardless of baseline state.
A critical area of ongoing scientific concern for Dihexa research is the biology of c-Met in cancer. HGF/c-Met signaling is oncogenic in multiple tumor types — amplification, mutation, or overexpression of c-Met is associated with poor prognosis in lung, gastric, liver, and other cancers, and several c-Met inhibitors are approved anticancer drugs. The question of whether chronic Dihexa administration, by potentiating c-Met signaling, could promote tumor growth or metastasis in individuals with occult malignancy or cancer predisposition is a serious theoretical concern that has not been adequately addressed in the current preclinical literature. Most Dihexa studies have used short treatment periods in aged rodents, which is insufficient to characterize tumor risk. This oncological uncertainty is one of the most important gaps in the Dihexa research literature and represents a meaningful constraint on its translational trajectory until long-term carcinogenicity studies are conducted.
The preclinical dose ranges reported in the Dihexa literature vary by route and model. In the published WSU behavioral studies, effective doses in rodents ranged from approximately 1 to 100 µg/kg for intraperitoneal and oral administration. The oral studies used doses at the higher end of this range to compensate for bioavailability losses, while IP studies often produced responses at lower doses. Given the enormous potency advantage claimed in vitro (107-fold over BDNF), the fact that in vivo doses are not similarly extreme relative to other research peptides likely reflects the practical realities of bioavailability, distribution, and CNS penetration rather than reduced potency at the receptor level. Human dose extrapolation from rodent data requires allometric scaling and should not be performed with simple mg/kg transposition, as CNS drug delivery kinetics differ substantially between species.
Dihexa has been studied in preclinical models via intraperitoneal injection, subcutaneous injection, oral gavage, and intranasal delivery. The oral and intranasal routes are of particular practical interest. Oral bioavailability has been functionally confirmed in behavioral studies. Intranasal delivery is theoretically attractive for direct CNS targeting, bypassing the blood-brain barrier via olfactory and trigeminal nerve pathways — a route that has been explored with a number of neuropeptides. Subcutaneous injection is the most common route used in peptide research settings for comparative purposes. Each route produces a different pharmacokinetic profile, and route selection should be determined by the specific research question and the time course of endpoints being measured.
Most published behavioral efficacy studies used relatively short treatment periods — days to a few weeks — with behavioral testing occurring during or immediately after the treatment period. The reversibility of Dihexa’s effects following discontinuation and the appropriate washout period before repeat-dose experiments are not well-characterized in the literature. Given that Dihexa appears to produce structural changes (new dendritic spines, synaptic remodeling), some effects may persist beyond the period of active drug presence, analogous to the persistence of long-term potentiation once established. Researchers designing repeat-dose or crossover protocols should allow conservative washout periods until pharmacodynamic duration data are better established. Consult the AI Coach for help structuring Dihexa research protocols.
Dihexa peptide is typically supplied as a lyophilized white powder. For parenteral administration, reconstitution in sterile saline or DMSO/saline mixtures has been used in preclinical studies, with DMSO sometimes included to enhance solubility given Dihexa’s lipophilic character. Oral gavage solutions have been prepared in water or buffered saline. The compound is reported to have good chemical stability as a lyophilized powder at −20°C. Reconstituted solutions should be protected from light and repeated freeze-thaw cycles. Purity of ≥95% by HPLC with mass spec confirmation is the standard benchmark for research-grade material. Use the peptide calculators for precise volumetric dosing calculations.
The published Dihexa preclinical literature does not extensively characterize toxicology — most studies were designed to evaluate cognitive efficacy rather than safety endpoints. The acute tolerability in the doses used in behavioral studies appears acceptable, with no reports of observable adverse behavioral or physical effects in treated animals at efficacious doses. No dedicated dose-escalation toxicity or maximum tolerated dose studies have been published in peer-reviewed literature, and this is a significant gap. Given the c-Met pathway’s importance in liver regeneration, kidney function, and gastrointestinal epithelial maintenance in addition to the brain, any compound that potentiates c-Met signaling system-wide warrants careful organ-level safety assessment before extended use.
As discussed in the research findings section, c-Met is a well-characterized proto-oncogene. Pharmacological potentiation of HGF/c-Met signaling through Dihexa could theoretically accelerate growth of pre-existing tumors, promote angiogenesis, or facilitate epithelial-mesenchymal transition in susceptible tissues. This is not a hypothetical concern invented by detractors — it is the same biology that makes c-Met inhibitors valuable cancer drugs, viewed from the opposite pharmacological direction. No long-term carcinogenicity or tumor promotion studies for Dihexa have been published. This represents a critical knowledge gap that should be addressed before any serious clinical translation is considered. Researchers should be aware of this risk when designing studies in cancer-prone animal models or when evaluating the compound in any context where occult neoplasia cannot be excluded.
At the time of this writing, no peer-reviewed human clinical trials of Dihexa have been published. The compound remains entirely in preclinical territory from an evidence-based safety perspective. Anecdotal reports from self-experimenting individuals circulate in online communities, but these carry no scientific weight given the complete absence of controlled conditions, blinding, standardized outcome measures, or safety monitoring. Researchers interested in Dihexa’s mechanisms are strongly advised to work within institutional research frameworks with appropriate ethical oversight, using validated preclinical model systems, rather than attempting human research outside of properly registered clinical trials. The Peptide Database entry for Dihexa tracks the evolving literature as new studies are published.
This figure comes from a specific in vitro synaptogenesis assay comparing the molar concentrations of Dihexa and BDNF required to produce a half-maximal synaptogenic response in hippocampal tissue. In that particular assay, Dihexa achieved equivalent synaptogenesis at a concentration roughly 107-fold lower than BDNF. This is an apples-to-oranges comparison in some respects — BDNF acts through an entirely different receptor (TrkB) and produces a somewhat different pattern of downstream effects — but the figure does convey that Dihexa’s mechanism operates at extraordinarily low effective concentrations in a synaptogenesis context. It should not be interpreted as a general pharmacological equivalence or as evidence that Dihexa replaces BDNF in all its physiological functions.
Yes, oral bioavailability has been demonstrated in preclinical rodent studies, which is quite unusual for a peptide compound. The hexanoyl (fatty acid) modification at the N-terminus is believed to be responsible for the increased lipophilicity and protease resistance that enables gastrointestinal survival and membrane absorption. Behavioral cognitive rescue studies were conducted using oral administration in some cases, providing functional evidence that the oral route delivers CNS-active concentrations. The precise oral bioavailability percentage and human pharmacokinetic extrapolation have not been formally published.
Most nootropic peptides work through direct receptor agonism (e.g., Semax acting on neurotrophin receptors), enzyme inhibition, or neuroprotection. Dihexa’s mechanism — allosteric potentiation of an endogenous growth factor’s binding to its receptor — is mechanistically distinct and relies on the presence of adequate endogenous HGF levels to produce effects. This means Dihexa functions as an amplifier of existing biology rather than a synthetic substitute for it. The downstream effects (synaptogenesis, dendritic spine growth, CREB activation) are more structurally profound than transient receptor activation, which may explain why effects persist beyond simple pharmacokinetic clearance in some studies.
Preclinical pharmacokinetic studies with radiolabeled Dihexa have demonstrated measurable brain uptake following peripheral administration, confirming CNS penetration. The lipophilic hexanoyl modification that confers oral bioavailability also facilitates passage across the blood-brain barrier through transcellular lipid diffusion. The brain-to-plasma ratio and regional CNS distribution have been partially characterized in rodents, with preferential uptake reported in hippocampus and cortex — the regions of highest c-Met expression. Whether equivalent CNS penetration occurs in humans remains to be established in formal human pharmacokinetic studies.
Dihexa was developed at Washington State University by Drs. Joseph Harding and John Wright in the College of Pharmacy. The foundational behavioral and mechanistic research was published primarily in the journal Neuropsychopharmacology around 2013–2014. The research built on the group’s long-standing work on angiotensin IV analogs and the AT4 receptor system (subsequently recharacterized as involving HGF/c-Met interactions) as a cognition-related pharmacological target.
As of the current literature, Dihexa remains a research compound without an active clinical development program that has reached published Phase I or Phase II human trials. The compound has been used as a proof-of-concept scaffold at WSU to demonstrate that allosteric HGF potentiation can rescue cognitive impairment, with the goal of informing development of more drug-like small molecule candidates. Patent filings related to the compound class suggest ongoing pharmaceutical interest, but the timeline and status of any IND application or formal clinical development program is not publicly documented in peer-reviewed literature.
The primary models used in published Dihexa research include aged Sprague-Dawley rats (a natural model of age-related cognitive decline), scopolamine-treated young rats (a pharmacological model of muscarinic blockade-induced amnesia), and organotypic hippocampal slice cultures for in vitro mechanistic studies. Some work has been performed in transgenic rodent models of Alzheimer’s disease pathology. The relatively narrow range of model systems is a limitation of the current evidence base — independent replication in diverse models, species, and laboratories would substantially strengthen confidence in the findings.
Dihexa was developed as a structural analog of angiotensin IV (Ang IV), the hexapeptide fragment of the renin-angiotensin system. Early research proposed that Ang IV’s cognitive effects were mediated by an “AT4 receptor,” which was later identified as the insulin-regulated aminopeptidase (IRAP). Subsequent research by the WSU group, however, argued that the relevant cognitive mechanism for Ang IV analogs including Dihexa is not IRAP but rather HGF/c-Met pathway potentiation. Whether IRAP inhibition also contributes to Dihexa’s cognitive effects remains a point of mechanistic debate in the literature, with the HGF/c-Met hypothesis currently holding more experimental support.
Disclaimer: This information is for research and educational purposes only. It is not medical advice. Consult a qualified healthcare professional before using any peptide.